Kymera Therapeutics, Inc.
KYMR
$82.21
-$2.29-2.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 55.50% | -61.18% | -26.12% | -55.26% | 114.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.50% | -61.18% | -26.12% | -55.26% | 114.83% |
| Cost of Revenue | 22.31% | 16.73% | 22.65% | 32.41% | 64.39% |
| Gross Profit | -9.70% | -25.67% | -25.87% | -99.43% | -50.93% |
| SG&A Expenses | 25.11% | 3.69% | 12.17% | 1.57% | 13.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.78% | 14.31% | 20.52% | 25.41% | 52.75% |
| Operating Income | -13.07% | -21.23% | -22.94% | -66.04% | -40.68% |
| Income Before Tax | -5.57% | -22.94% | -31.51% | -82.15% | -35.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.57% | -22.94% | -31.51% | -82.15% | -35.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.57% | -22.94% | -31.51% | -82.15% | -35.06% |
| EBIT | -13.07% | -21.23% | -22.94% | -66.04% | -40.68% |
| EBITDA | -13.48% | -21.57% | -23.77% | -67.06% | -40.69% |
| EPS Basic | 13.26% | -9.37% | -14.68% | -65.42% | -19.27% |
| Normalized Basic EPS | 13.24% | -9.37% | -9.30% | -65.43% | -32.73% |
| EPS Diluted | 13.26% | -9.37% | -14.68% | -65.42% | -19.27% |
| Normalized Diluted EPS | 13.24% | -9.37% | -9.30% | -65.43% | -32.73% |
| Average Basic Shares Outstanding | 21.70% | 12.41% | 14.68% | 10.12% | 13.25% |
| Average Diluted Shares Outstanding | 21.70% | 12.41% | 14.68% | 10.12% | 13.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |